BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: ADAM metallopeptidase with thrombospondin type 1 motif 13 (ADAMTS13)

September 10, 2015 7:00 AM UTC

In vitro studies suggest a modified form of ADAMTS13 could help treat thrombotic thrombocytopenic purpura (TTP). Autoantibodies from TTP patients inhibit ADAMTS13-mediated cleavage of von Willebrand f...